The Global Anti-infectives Market Outlook to 2011
The anti-infectives market is forecast to expand at a CAGR of 4.8% over the period 2005-11, riven largely by gains in the anti-bacterial and anti-viral classes. This represents significant market opportunity for pharma companies to expand their sales potential by targeting high growth markets. The Global Anti-infectives Market Outlook to 2011 provides comprehensive coverage of the anti-infectives market, incorporating a detailed epidemiological analysis of the major indications and the key factors impacting their prevalence. Analysis of the major brands and profiles of the leading pharmaceutical companies will ensure that you can plan effectively, evaluate key changes in the competitive landscape, and identify potential growth areas within the global anti-infectives market. Use this report to assess anti-infective therapies that will be crucial to maintaining positive sales growth, analyze the marketed product portfolio and R&D pipelines of the leading 10 pharmaceutical companies in the global anti-infectives market.

Key findings of the report...
• The anti-infectives market is forecast to expand at a CAGR of 4.8% over the period 2005-11. Growth is forecast to be driven by gains in the anti-bacterial and anti-viral classes, with anti-bacterials expanding at a low rate, due to the sheer size of the class.
• Anti-bacterials occupied the leading position in the anti-infectives market in 2005 with a market share of 59.9% and $33,919m in sales for the same year. The major growth driver in this drug class are the macrolides and the beta-lactams drug classes which together reported combined sales of $7,963m or some 23.5% of total anti-bacterial sales.
• Anti-fungals was the only drug class to record negative growth in 2004-5 reported at -4.4% having witnessed a decline of $207m from 2004 sales of $4,646m to $4,439m in 2005. This decrease in sales growth has been attributed to the low levels of product proliferation and innovation in this drug class.
• With limited levels of new product introductions, particularly within the anti-fungal and anti-bacterial drug classes, generic competition is a major factor shaping the anti-infectives market, which saw sales of generic products increase by 15.8% in 2005 to $21.0bn from $18.1bn in the previous year.

Key questions answered in this report
• What will be the major growth indications in the anti-infectives area over the period 2006-11?
• What are the current trends within the major therapy areas of anti-fungals, anti-bacterials, anti-virals and vaccines across the seven major markets?
• How have recent launches from companies such as GSK, BMS, J&J, Roche and Wyeth performed?
• What are the most exciting compounds currently in development for anti-infectives indications, and what is the forecast market potential of these products?
• How significant is the threat of generics to the overall performance of the global anti-infectives market?
• Which companies are best positioned to succeed in the global anti-infectives market over the period 2006-11?

Top five reasons to order your copy today
• Quantify patient potential, assess treatment trends and sales patterns across the 5 major anti-infective indications, the US, Japanese and top EU5 markets and the 10 leading companies.
• Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of major classes of anti-infective treatments including anti-virals, anti-bacterials, anti-fungals and vaccines.
• Evaluate how market share of leading companies, such as GSK, Pfizer, Abbott, BMS and Wyeth will change over the next 6 years and position yourself for success.
• Benchmark forecast perfomance of the leading players by using analysis of key products in major indications over the period 2006 to 2011.
• Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.